Hi @aatisket
I think you may have misread my post.
I said I believe the combination of a phase 3 interim and a positive phase 2b, both evaluating MPCs on CHF (what Teva returned to MSB at no cost) would unequivocally prove that Teva did not return the CHF program to MSB due to poor results (which is what a lot of people in this forum wanted us to believe).
Phase 2b CHF (LVAD) clinical trial, page-8
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
-0.010(0.76%) |
Mkt cap ! $1.495B | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.33 | $1.28 | $1.819M | 1.396M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 29972 | $1.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 2008 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |